Deals & regulation
Novartis India buys Pfizer trademarks for $132 million as Minipress XL exits
Novartis India agreed to pay Rs12.5 billion ($132 million) for the Indian Minipres and Minipress trademarks and associated intellectual property from Pfizer entities. The purchase adds an established hypertension brand, but coincides with Pfizer ending Indian sales of Minipress XL after its US parent decided to stop manufacturing the product. The report does not explain future supply arrangements. Citing IQVIA, Novartis India put the brand’s annual revenue through July 2026 at Rs2.28 billion.
Editorial summary · Feed excerpt
What matters
- The agreement covers Indian trademarks and certain related intellectual property rights.
- Pfizer said marketing, distribution and sales of Minipress XL would stop from September 7.
- The brand’s four-year annual growth of 6.3% lagged the category’s 9%.
Context & caveats
- The acquisition does not, on the supplied evidence, establish continued product availability.
Why this made the edition
Substantive filing-based acquisition report with price, asset scope, sales context and a material product-withdrawal caveat.
Source material